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Antibacterial activityAbstract In the present investigation, a novel series of pyrazolines 2a–2d were synthesized by the
cyclization of various -1-[2-(alkoxy) phenyl]-3-(thiophen-2-yl) prop-2-en-1-one 1a–1d with N-substi-
tuted phenyl hydrazine and thiosemicarbazide in the presence of CH3COOH and NaOH in ethanol
which lead to the formation of new pyrazolines. The structures of these compounds were elucidated
by, IR, 1H-NMR, 13C-NMR, ESI-MS spectral data and their purities were conﬁrmed by elemental
analyes. The in vitro antibacterial activity of these compounds was evaluated against two Gram-
positive and two Gram-negative bacteria Aeromonas hydrophila, Yersinia enterocolitica, Listeria
monocytogenes, and Staphylococcus aureus by microdilution method and then the minimum inhib-
itory concentration (MIC) of these compounds was determined. The results showed that com-
pounds 1-[2-(benzyloxy) phenyl]-5-(thiophen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl (2b) and
1-[2-(naphthalen-2-ylmethoxy) phenyl]-5-(thiophene-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazole-4-yl
(2d) showed most promising antibacterial activity as compared to the antibiotics gentamicin and
tetracycline in (Tables 1 and 2).
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Open access under CC BY-NC-ND license.1. Introduction
Emerging pathogenous infections such as gastroenteritis,
arthritis, listeriosis and pneumonia are caused by multidrug-resistant Gram-positive and Gram-negative pathogens. These
diseases are the world’s most prevalent and fatal infectious dis-
eases. Principal players among these problematic organisms
are isolates of methonia resistant Aeromonas hydrophila, Yer-
sinia enterocolitica, Listeria monocytogenes, and Staphylococ-
cus aureus (Daskalov, 2006; Andersen, 1988; Ogston, 1984;
Saginur and Suh, 2008). It is speculated that resistance to b-
lactam antibiotics is due to the production of multiple induc-
ible, chromosomally encoded b-lactames. Resistance to the
third generation cephalosporins is known to be associated with
the derepression of the chromosomal enzymes (Gonˇi-Urriza
et al., 2000). In rare cases, through direct inactivation of the
antibiotic or by mutations in the 16S rRNA that prevent the
412 M. Rani, Y. Mohamadbinding of tetracycline to the ribosome. Amoxicillin, penicillin,
ampicillin, norﬂoxacin, Oﬂoxacin and ciproﬂoxacin are the
principal drugs of choice in the treatment of bacterial infection
since they are effective against extraintestinal and intestinal
wall infection (Ko et al., 1996), but these are associated with
several side effects such as nausea, metallic taste, dizziness,
hypertension, etc. as well as resistance have been reported
(Bauer et al., 1996; Doyle et al., 2007). The present strategy
for new drug development is directed towards identifying the
essential enzyme systems in the bacterial and developing mol-
ecules to inhibit them on our ongoing medicinal chemistry
research activity. The study of chalcone derivatives has become
of much interest in recent years on account of their antibacte-
rial, antiviral, anti-cancer, anti-fungal, anti-hermitic and insec-
ticidal (Marc et al., 2008; Babasaheb et al., 2010; Detsi et al.,
2009) activities. Cyclization of chalcone such as pyrazolines
dramatically increases the diversity of certain biological prop-
erties such as antibacterial, antiviral and anti-amoebic activi-
ties (Solankee et al., 2010; Zitouni et al., 2005; Fathalla
et al., 2003). In view of these observation and in continuation
of our group work on biologically active heterocyclic com-
pounds (Clark et al., 2008; Khan, 2008; Khan and Yusuf,
2009a,b) and their increasing importance in pharmaceutical
and biological ﬁeld, it was considered of interest to synthesize
some new chemical entities incorporating the molecular frame
work and to evaluate their biological activities. In this regard,
alkloxy chalcones would be suited for preparing pyrazoline. In
this paper we have to synthesis a novel series of pyrazoline
derivatives from alkoxy chalcone as antibacterial agents.
2. Chemistry
The present investigations were synthesized starting from the
Claisen–Schmidt reaction of acetophenone with 2-thiophene
carboxaldehyde in the presence of NaOH (50%) to give 95%
yield of the starting material (2E)-l-(2-hydroxyphenyl)-3-(thio-
phen-2-yl) prop-2-en-1-one a. The -1-[2-(alkoxy) phenyl]-3-
(thiophen-2-yl) prop-2-en-1-one 1a–1d were prepared in good
yields from the O-alkylation of (a) with suitable alkylating
agents (like allylbromide, benzyl chloride, bromoethylacetate,
1-chloromethylnapthalene) in the presence of K2CO3/PTC/
dry acetone, under the similar condition, were prepared by
the reported method. The cyclization of the latter with phenyl
hydrazine in the presence of CH3COOH in ethanolic condition
led to formation of new compounds such as 1-[2-(alkoxy) phe-
nyl]-3-(thiophen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl
2a–2d, which were crystallized from CHCl3:CH3OH (1:3) to
give pure crystalline solid compounds in moderate yields. All
the compounds are insoluble in water but soluble in organic
solvents. The structures of these compounds 1a–1d and 2a–
2d were analyzed by the rigorous analysis of their IR, 1H-
NMR, 13C-NMR and ESI mass spectral data.
3. Pharmacology
Antibacterial activity of newly synthesized pyrazoline com-
pounds were evaluated against various pathogenic bacterial
strains (Gram-negative and Gram-positive) viz., A. hydrophila,
Y. enterocolitica, L. monocytogenes and S. aureus. The antibac-
terial activities were evaluated by agar disc diffusion method.
The solvent, DMSO used for the preparation of compoundsdid not show inhibition against the tested organisms. The
results of antibacterial activity and minimum inhibitory con-
centration (MIC) are summarized in Tables 1 and 2,
respectively.
3.1. Material and method
Pure cultures of A. hydrophila, Y. enterocolitica, L. monocytog-
enes and S. aureus were grown in brain heart infusion broth for
sensitivity testing. Mueller Hinton agar (Hi Media) and pyraz-
oline compounds 2a–2d absolutely diluted (concentration of
40, 30, 20 and 10 mcg) were applied as described by Bauer
et al. (1996) and Doyle et al. (2007). The strains were tested
against the following antibiotics (Hi- Midia): gentamicin
10 mcg, tetracycline 30 mcg. These were enriched with BHIB
for 6–8 h at 37 C, the cultures were streaked on Mueller Hin-
ton agar plates using a cotton swab. With an antibiotic disc
dispenser, the discs were placed on the agar surface. After
30 min of pre-diffusion time, the plates were incubated at
37 C for 18–24 h, after incubation, the diameter of the inhibi-
tion zones were measured and compared to the interpretive
chart of performance standards for antimicrobial disc suscep-
tibility tests (Hi Media) and classiﬁed as resistant, intermediate
or sensitive.
3.2. In vitro antibacterial activity
In vitro antibacterial activities of pyrazoline 2a–2d derivatives
were carried out using the culture of A. hydrophila, Y. entero-
colitica, L. monocytogenes and S. aureus by the disc diffusion
method and then minimum inhibitory concentration (MIC)
of these compounds were determined. Gentamicin and tetracy-
cline antibiotics were used as the standard drugs, where as
DMSO poured disc was used as negative control. The mini-
mum inhibitory concentration (MIC) was evaluated by the
microdilution method of test compounds, previously dissolved
in dimethyl sulphoxide (DMSO) which was prepared to ﬁnal
concentration of 40, 50, 30, 20 and 10 l/ml. The MIC, deﬁned
as the lowest concentrations of the test compounds, which
inhibits the visually growth was determined after incubation
for 18 h, at 37 C. The in vitro studies result showed that the
compounds 2b and 2d are more active among all the pyrazo-
lines. Compounds 2b and 2d are better antibacterial agents
as compared to antibiotics. The susceptibility of the bacteria
to the test compounds was determined by the formation of
an inhibitory zone after 48 h of incubation at 37 C.
These compounds showed the highest activity of 2b and 2d
against A. hydrophila, Y. enterocolitica, L. monocytogenes and
S. aureses. The molecular structure of these active compounds
showed property of the pyrazolines which might be more efﬁ-
cacious drugs against these bacteria and their biological effects
which could be helpful in designing more potent antibacterial
agents for therapeutic use.
4. Results and discussion
All the four synthesized compounds 2a–2d were screened for
their potential to inhibit emerging pathogens A. hydrophila,
Y. enterocolitica, L. monocytogenes and S. aureus responsible
for gastrointestinal diseases. The present study describes the
synthesis and antibacterial evaluation of some 1-[2-(alkoxy)
Table 1 Antibacterial activity of pyrazoline derivatives, positive control (gentamicin and tetracycline) and negative control (DMSO)
measured by the halo zone test (unit, mm).
Compounds Corresponding eﬀect on micro-organisms (unit, mm)
A. hydrophila Y. enterocolitica L. monocytogenes S. aureus
2a 14.5 11.5 13.4 14.6
2b 20.5 22.4 24.3 22.8
2c 12.5 14.5 14.5 15.5
2d 21.7 18.4 21.2 19.4
Gentamicin 21 – – 17
Tetracycline 13 20 12 14
DMSO – – – –
Table 2 Minimum inhibition concentration (MIC) of bis-pyrazoline derivatives and positive control (gentamicin and tetracycline)
(unit, mcg).
Compounds (MIC) (MIC) Corresponding eﬀect on micro-organisms (unit, mcg)
A. hydrophila Y. enterocolitica L. monocytogenes S. aureus
2a 10 10 10 10
2b 30 30 30 30
2c 40 40 40 40
2d 20 20 20 20
Tetracycline 30 30 30 30
Gentamicin 10 10 10 10
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yl 2a–2d pyrazoline derivatives of -1-[2-(alkoxy) phenyl]-3-
(thiophen-2-yl) prop-2-en-1-one 1a–1d and development of a
series of new pyrazoline derivatives which were synthesized
in satisfactory yields (62–80%) as illustrated in Fig. 1 and their
structures were characterized by spectral data. Selected com-
pounds 2a, 2b, 2c, 2d, and 2e showed similar results when
tested against A. hydrophila, Y. enterocolitica, L. monocytoge-
nes and S. aureus. The compounds 2a and 3a exhibit more
activity as compared to the standard drugs Gentamicin
(10 mcg) and Tetracycline (30 mcg). On the basis of the above
observations, modiﬁcation will be done to improve antibacte-
rial activity.
4.1. IR spectral studies
Assignment of selected characteristic IR bands provides signif-
icant indications for the formation of the cyclized pyrazoline(A)
3 4
5N
N
SHx
Ha
Hb
O CH2 R
Figure 1 Schematic diagram indicating the ring conformation of
compound nos. 2a–2d.analogues of the phenyl hydrazine 2a–2d. In started material
chalcones (C‚O) and (CH‚CH), functional absorbed in
the expected region; (C‚O) at 1597–1655 cm1 and
(CH‚CH) at 1585–1598 cm1, respectively. The IR spectra
of the compounds showed t(C‚N) stretching at 1586–
1601 cm1. In addition, the absorption bands at 995–
1034 cm1 were attributed to the t(C–N) stretching vibration,
which also conﬁrm the formation of desired pyrazoline
compounds.
4.2. 1H-NMR spectral analysis
The 1H-NMR spectra (400 MHz, CDCl3), the
1H-NMR of the
starting material chalcone 1a–1d were the two broad doublets
centred at d 7.71–7.82 and 6.92–7.65 which could be ascribed
to H-3 and H-2 protons, respectively, and coupling value of
15.4–15.7 Hz between these hydrogens describe the trans
geometry around the C-2 and C-3 double bond. The downﬁeld
resonance of the H-3 as compared to H-2 could be ascribed to
the electron deﬁcient nature of the b-carbon in the enone moi-
ety. Other signiﬁcant signals in the aromatic region appeared
at d 6.7–7.9, respectively. The major features of this spectrum
were the signals of the pyrazoline 2a–2d ring proton (H-x) and
(H-a and b) which were found in the region at d 5.12–5.32 (1H,
dd, Jxa = 6.5–6.7 Hz, Jxb = 11.6–11.8 Hz,) and 3.42–3.82 ppm
(1H, dd, Jax = 6.4–6.7 Hz, Jab = 16.8–17.6 Hz), respectively.
The pyrazoline proton (H-b) and –CH2 protons appeared
together at d 4.01–5.49 ppm. In a double resonance experi-
ment, irradiation of doublet of doublet at d 5.12 (H-x) con-
verted the doublet of doublet at 3.2 (H-a) to doublet at d
4.01–5.49 ppm, which clearly describes the inter-relationship
between the H-x, b and a. The proposed expression 2a–2d is
due to vicinal coupling with two magnetically non-equivalent
414 M. Rani, Y. Mohamadgeminal proton of adjacent carbon atom C5 pyrazoline ring.
The strong deshielding of the C5 (H-a and b) protons com-
pared with the C4 (H-x) protons of the pyrazoline ring can
be assumed due to its structure Fig. 2. The protons belonging
to the aromatic ring and the other cyclic groups were observed
with the expected chemical shift and integral values.
Finally, 13C-NMR (400 MHz, CDCl3) spectra of all com-
pounds were recorded in DMSO and spectral signals which
are in good agreement with the probable structures. The meth-
ylene groups for 1c & 2c were resonating at d 22.4–54.2 (CH3)
and 72.2–72.4 (OCH2); the downﬁeld resonance of the former
suggests their placement near an electronegative oxygen atom.
The carbon of –CH2 in all compounds resonates at 62.5–
74.2 ppm, respectively. The C4 and C5 carbon of pyrazolines
2a–2d resonated at 61.5–64.8 and 67.6–74.2 ppm, respectively.
The carbon of –CH3 in all compounds resonates at 22.4–
24.5 ppm, respectively. The carbon of (C‚O) and (C‚C) dis-
played signals at 190.5–192.2 and 137.6–144.6 ppm in 1a–1d
compounds. All the compounds showed signal at 112.8–
155.8 ppm were assigned to the aromatic carbon. The com-
pounds 2a–2d showed two signals at 155.6–156.7 ppm assigned
to (C‚N), respectively. The signals were due to the aromatic
carbons and the carbon at 1-N-substituted aliphatic group.
The other resonances were visible at their usual position in
Section 5.O
H
S
+
OH
O
CH3
0 
PTC=Bu 4N
+
I
-
where  R = -CH=CH 2,  -Ph,   -COOEt,
(1a,2a ) (1b, 2b) (1c, 2c) (1d, 2d)
X = -Cl,  Br
Figure 2 Schematic diagram indicating t4.3. ESI mass analysis
Characteristic peaks were observed in the mass spectra of all
compounds, which followed the similar fragmentation pattern.
The spectrum of the compound 2a showed a molecular ion
peak (M+) at m/z 411. The characteristics peaks observed
within the mass spectra of pyrazoline compound are given in
the experimental section.
It may be concluded that this study describes the general
method for the synthesis of some pyrazolines linked through
the 5-aryl ring under the normal conditions. These results
show that the compounds 2b & 2d show highest antibacterial
activity and overall compounds exposed sufﬁcient activity
against A. hydrophila, Y. enterocolitica, L. monocytogenes
and S. aureus promising antibacterial activity. Thus the accu-
mulation of the pyrazoline derivatives will be a better antibac-
terial agent as compared to gentamicin and tetracycline.
5. Experimental
The entire chemicals were purchased from Aldrich Chemical
Company (USA) and were used without further puriﬁcation.
The reactions were monitored by percolated aluminium silica
gel 60F 254 thin layer plates procured from Merck (Germany).
All melting points were measured with a capillary apparatusNaOH
oC / EtOH
K2CO 3 / PTC /
PhNHNH 2 /
EtOH / 
O
O
CH2 R
S
2a -2d
1a -1d
glacial acitic acid
 dry acetone
1
Δ
OH
O
S
2
3
3
2
R-CH 2-X /
3 4
5N
N
SHx
Ha
Hb
O CH2 R
he synthesis of compound nos. 2a–2d.
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checked by IR, 1H-NMR, 13C-NMR, mass spectrometry and
elemental analyses. IR spectra were recorded in KBr on a Per-
kin–Elmer model 1620 FTIR spectrophotometer. 1H-NMR
and 13C-NMR spectra were recorded at an ambient tempera-
ture using Brucker spectrospin DPX-400 MHz spectropho-
tometer in CDCl3 and DMSO. The following abbreviations
were used to indicate the peak multiplicity s – singlet, d – dou-
blet, t – triplet, m – multiplet. The mass spectra have been
scanned on the Waters Micromass Q-T of Micro (ESI) spec-
trometer. Anhydrous sodium sulfate was used as a drying
agent for the organic phase.
5.1. General procedure for the synthesis of (2E)-l-(2-
hydroxyphenyl)-3-(thiophen-2-yl) prop-2-en-1-one (1)
A suspension of O-hydroxy acetophenone (1 equiv.) and thio-
phene carboxaldehyde (1 equiv.) in ethanolic solution of
NaOH (30%) was stirred for 8 h at room temperature. After
the completion of the reaction, the reaction mixture was
poured into acidic ice water  pH 2 (adjusted by HCl) to pro-
duce a solid compound which was ﬁltered under suction and
washed with H2O. The solid was ﬁltered recrystallized from
CH3OH:CHCl3 (3:1) to obtain a pure chalcone 1 (Husain
et al., 2008).
Yellow needles; Yield: 95%; m.p. 86 C; Anal. calc. for
C13H10O2S: C, 67.82; H, 4.34; Found: C, 67.78; H, 4.30 %;
IR (KBr) tmax (cm
1): 1636 (C‚O), 2952 (OH); 1H-NMR
(400 MHz, CDCl3): d (ppm): 12.86 (1H, s, –OH), 8.04 (1H ,d
Jtrans = 15.4 Hz, H-3), 7.82 (1H, d, Jtrans = 15.4 Hz, H-2)
7.49 (1H, d{dd}, Jp,m,o = 1.4, 3.6, 7.1 Hz, Ar-H), 7.45 (1H,
m, Ar-H), 7.43 (1H, m, Ar-H), 7.01 (1H, dd, Jm,o = 3.6 Hz,
7.1 Hz,Ar-H), 7.34 (1H, t, Ar-H), 7.10 (1H, t, Ar-H), 6.82
(1H, t, Ar-H); 13C-NMR (400 MHz, CDCl3): d (ppm): 191.4
(C‚O), 154.7, 149.6, 148.4, 143.8 (C‚C), 138.7 (C‚C),
133.5, 128.8, 127.5, 127.8, 125.8, 124.7, 122.6, (Ar-C); GC–
MS m/z (rel. int. %): 231 (68) [M + 1]+.
5.2. General procedure for the synthesis of (2E)-1-[2-(prop-2-
en-1-yloxy) phenyl]-3-(thiophen-2-yl) prop-2-en-1-one (1a)
A suspension of l-(2-hydroxyphenyl)-3-(thiophen-2-yl) prop-2-
en-1-one (1) (2.0 g, 0.005 mol), allyl bromide (1.5 ml,
0.0041 mol), freshly ignited K2CO3 (1.0 g) and tetrabutylamo-
nium iodide as PTC (1.0 g) in dry acetone (25 ml) was heated
at reﬂux for 1 h with stirring. In the absence of PTC, reaction
occurred in 70–80 h and yields of the alkoxy chalcones were
obtained. Use of PTC in these reactions, not only decreased
the reaction time up to 4–5 h but also improved the yield of
1-[2-(prop-2-en-1-yloxy) phenyl]-3-(thiophen-2-yl) prop-2-en-
1-one derivatives up to 80–85%. The products thus obtained
were puriﬁed by passing through a silica gel column (60–120
mesh) and further crystallized from methanol to afford 1a
(Kumar and Yusuf, 2006).
Light brown; Yield: 92%; m.p. 82 C; Anal. calc. for
C16H14O2S: C, 71.11; H, 5.18, Found: C,71.07; H, 5.15 %;
IR (KBr) tmax (cm
1): 2923, 2871 (C–H), 1651 (C‚O), 1590
(C‚C); 1H-NMR (400 MHz, CDCl3): d (ppm): 7.78 (1H, d,
Jtrans = 15.6 Hz, H-3), 7.62 (1H, d{dd}, Jp,m,o = 0.8, 1.8,
7.8 Hz, Ar-H), 7.30 (1H, d, Jtrans = 15.6 Hz, H-2), 7.04 (2H,
m, Ar-H), 7.44 (1H, d, J= 1.8,7.8 Hz, Ar-H), 7.36 (1H, d,J= 5.2 Hz, Ar-H), 7.28 (1H, d, J= 5.8 Hz, Ar-H), 6.96
(1H, d, J= 5.0 Hz, Ar-H), 6.05 (1H, q, J = 6.7 Hz, –CH),
5.45 (2H, td, Jvis=1.7, 17.2 Hz –CH2), 5.25 (2H, td, Jvic = 6.4 -
Hz, –CH2);
13C-NMR (400 MHz, CDCl3): d (ppm): 192.2
(C‚O), 154.5, 153.6, 144.6 (C‚C), 141.5 (C‚C), 132.2,
131.6, 130.2 128.6, 126.2, 125.3, 120.2 122.3 (Ar-C), 68.4
(CH2), 62.5 (CH2), 60.3 (CH); MS: m/z (M
+) 271.
5.3. (2E)-1-[2-(benzyloxy) phenyl]-3-(thiophen-2-yl) prop-2-
en-1-one (1b)
A suspension of l-(2-hydroxyphenyl)-3-(thiophen-2-yl) prop-2-
en-1-one (1) (2.0 g, 0.001 mol), benzyl chloride (1.5 g,
0.004 mol), under similar conditions as used for 1a and was
further crystallized from methanol to afford 1b.
Light yellow; Yield: 95 %; m.p. 85 oC; Anal. calc. for
C20H16O2S: C, 75.0; H, 5.0; Found: C, 74.7; H, 4.6%; IR
(KBr) tmax (cm
1): 3074(Ar-H), 1597 (C = O), 1597
(CH= CH); 1H-NMR (400 MHz, CDCl3): d /ppm: 7.71
(1H, d, Jtrans = 15.7 Hz, H-3), 7.56 (4H ,m, Ar-H), 7.42 (2H,
dd, J = 7.6 Hz, Ar-H), 7.05 (1H, d{dd}, Jp,m,o = 0.8,1.2,7.6 -
Hz, Ar-H), 7.32 (3H, m, Ar-H), 7.03 (1H, m, Ar-H), 6.92
(1H, d, Jtrans = 15.7 Hz, H-2), 6.8 (1H, d, J= 7.6 Hz, Ar-
H), 5.18 (2H, s, –CH2);
13C-NMR (400 MHz, CDCl3): d
(ppm): 191.4 (C‚O), 154.7, 153.2, 149.6, 143.8 (C‚C),
142.1, 138.7 (C‚C), 132.5, 131.5, 130.7, 129.2, 129.2, 128.7,
128.7, 127.5, 126,2, 125.8, 124.3, 122.4 (Ar-C), 74.2 (CH2);
GC–MS m/z (rel. int. %): 321 (72) [M + 1]+.
5.4. (2E)-1-[2-(ethyloxy) phenyl]-3-(thiophen-2-yl) prop-2-
en-1-one (1c)
A suspension of (1) (2.0 g, 0.01 mol), bromoethyl acetate
(1.2 g, 0.004 mol), under similar conditions was used for 1a
and was further crystallized from methanol to afford 1c.
Light brown; Yield: 86%; m.p. 89 C; Anal. calc. for
C17H16O4S: C, 64.55; H, 5.06; Found: C, 64.52; H, 5.02 %;
IR (KBr) tmax (cm
1): 2980, 2933 (methylene C–H), 3075
(Ar-H), 1655, 1751 (C‚O), 1598 (CH‚CH); 1H-NMR
(400 MHz, CDCl3): d (ppm): 7.82 (1H, d, Jtrans = 15.6 Hz,
H-3), 7.65 (1H, dd, Ar-H), 7.45 (1H, d{dd}, Jp,m,o = 0.7,
1.8, 7.5 Hz, Ar-H), 7.40 (2H, d, J = 1.0,7.6, Ar-H), 7.36 (1H,
d, Jtrans = 15.6 Hz, H-2), 7.07 (2H, m, Ar-H), 6.8 (1H, d,
J= 1.0,7.6, Ar-H), 4.73 (2H, s, –CH2), 4.25 (2H, q,
Jvic = 7.1 Hz, –OCH2), 1.25 (3H, t, Jvic = 7.2 Hz, –CH3);
13C-NMR (400 MHz, CDCl3): d (ppm): 191.2 (2C‚O),
144.6 (C‚C), 155.8, 154.5 148.5, 142.6 (C‚C), 131.7, 130.3,
128.5, 127.4, 126.6, 125.4, 121.6 (Ar-C), 72.4 (OCH2), 68.4
(CH2), 22.4 (CH3); MS; m/z (M
+) 317.
5.5. (2E)-1-[2-(naphthalen-2-ylmethoxy) phenyl]-3-(thiophen-
2-yl)prop-2-en-1-one (1d)
A suspension of (1) (2.0 g, 0.01 mol), 1-chloromethylnaptha-
lene (1.4 g, 0.004 mol), under similar conditions as used for
1a and was further crystallized from methanol to afford 1d.
Light brown; Yield: 88%; m.p. 94 C; Anal. calc. for
C24H18OS: C, 77.83; H,4.86; Found: C, 77.80; H, 4.82 %; IR
(KBr) tmax (cm
1): 3064 (Ar-H), 1637 (C‚O), 1592
(CH‚CH); 1H-NMR (400 MHz, CDCl3): d (ppm): 8.02 (1H,
m, Ar-H), 7.83 (1H, d, J= 8.1 Hz, Ar-H), 7.80 (1H, d,
416 M. Rani, Y. MohamadJtrans = 15.4 Hz, H-3), 7.74 (1H, dd, J= 1.8, 7.4 Hz, Ar-H),
7.65(1H, d, Jtrans = 15.4 Hz, H-2), 7.61 (2H, d, J = 1.9,
7.6 Hz, Ar-H), 7.24 (4H, m, Ar-H), 7.42 (1H, d{dd},
Jp,m,o = 0.8, 1.9, 7.6 Hz, Ar-H), 7.09 (2H, m, Ar-H), 6.92
(2H, m, Ar-H), 5.59 (2H, s, –CH2);
13C-NMR (400 MHz,
CDCl3): d (ppm): 190.5 (C‚O), 155.7, 151.7, 142.7 (C‚C),
137.6 (C‚C), 144.4, 132.5, 131.4, 130.6, 129.5, 129.5, 128.2,
128.2, 127.5, 126.7, 125.4, 124.5, 122.5, 122.5, 121.3, 120.6,
118.9, 118.9 (Ar-C), 66.5 (CH2); m/z (M
+) 371.
5.6. General procedure for the synthesis of 1-[2-(allyloxy)
phenyl]-5-(thiophen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-4-
yl (2a)
A mixture of -1-[2-(prop-2-en-1-yloxy) phenyl]-3-(thiophen-2-
yl) prop-2-en-1-one (1a) (0.5 g, 0.0015 mol) was reﬂuxed with
phenyl hydrazine (0.800 ml, 0.004 mol) in dry EtOH (30 ml)
and catalytic amount of glacial acetic acid for at 80 C for
8 h. The progress of the reaction was monitored by TLC. After
completion of the reaction, the solvent was removed under
reduced pressure and the residue obtained was puriﬁed by col-
umn chromatography (20:80, diethyl ether:petroleum ether)
the obtained solid was crystallized from EtOH to yield pyraz-
olines 2a.
Dark brown; Yield: 88 %; m.p. 134 C; Anal. calc. for C22-
H20N2OS: C, 73.33; H, 5.55; Found: C, 73.30; H, 5.52 %; IR
(KBr) tmax (cm
1): 3037 (Ar-H), 3319 (N–H), 1595 (C‚N);
1H-NMR (400 MHz, CDCl3): d (ppm): 7.72 (3H, m, Ar-H),
7.51 (5H, m, Ar-H), 7.04 (2H, d, Ar-H), 6.80 (1H, d,
J= 7.6 Hz, Ar-H), 6.32 (1H, d{dd}, Jp,m,o = 1.0, 1.8,
7.6 Hz, Ar-H), 5.06 (1H, dd, Jvic = 1.1 Hz,7.0 Hz, –CH),
4.95 (2H, t, J= 6.4 Hz, –CH2), 4.25 (2H, dd, –CH2), 5.32
(1Hx, dd, Jxa = 6.7 Hz, Jxb = 11.7 Hz), 3.51 (1Ha, dd,
Jax = 6.7 Hz, Jab = 16.8 Hz), 3.22 (1Hb, dd, Jbx = 11.7 Hz,
Jba = 16.8 Hz);
13C-NMR (400 MHz, CDCl3): d (ppm):
155.6 (C‚N), 153.4, 152.4, 150.2, 144.2, 132.5, 130.2, 129.9,
129.9, 128.2, 128.2, 127.3, 126.3, 125.8, 123.1, 121.2, 116.6,
114.2 (Ar-C), 72.2 (pyr. ring, C-5), 71.1 (CH), 69.4 (CH2),
63.1 (pyr. ring, C-4); m/z (M+) 361.
5.7. 1-[2-(Benzyloxy) phenyl]-5-(thiophen-2-yl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl (2b)
Pyrazoline 2b was obtained from the reaction of -1-[2-(banzyl-
oxy) phenyl]-3-(thiophen-2-yl) prop-2-en-1-one 1b 1a (0.5 g,
0.0015 mol) with phenyl hydrazine (0.430 g, 0.00398 mol)
under similar conditions was used for 1a and was further crys-
tallized from ethanol to afford 2b.
Blackish brown; Yield: 92%; m.p. 128 C; Anal. calc. for
C26H22N2OS: C, 76.09; H, 5.36; Found: C, 76.05; H, 5.32 %;
IR (KBr) tmax (cm
1): 3037 (Ar-H), 3319 (N–H), 1595
(C‚N); 1H-NMR (400 MHz, CDCl3): d (ppm): 7.91 (5H,
m, Ar-H), 7.34 (2H, m, Ar-H), 7.28 (3H, m, Ar-H), 7.06
(1H, d{dd}, Jpmo = 1.0, 1.8, 7.0 Hz, Ar-H), 6.9 (5H, m,
Ar-H), 6.81 (1H, m, Ar-H), 5.25 (1Hx, dd, Jxa = 6.5 Hz,
Jxb = 11.8 Hz), 5.01 (2H, s, –CH2), 3.82 (1Ha, dd, Jax = 6.5 -
Hz, Jab = 17.2 Hz), 3.42 (1Hb, dd, Jbx = 11.8 Hz,
Jba = 17.2 Hz);
13C-NMR (400 MHz, CDCl3): d (ppm):
155.7 (C‚N), 153.3, 152.2, 144.2, 142.2, 132.6, 131.8,
130.4, 129.2, 129.2, 128.7, 127.5, 126.4, 126.4, 125.8, 124.3,
124.3, 122.3, 122.3, 121.5, 120.6, 118.6, 115.6 (Ar-C), 74.2(pyr. ring, C-5), 63.6 (CH2), 64.8 (pyr. ring, C-4); m/z
(M+) 411.
5.8. 1-[2-(Ethyloxy) phenyl]-5-(thiophen-2-yl)-1-phenyl-4,5-
dihydro-1H-pyrazol-4-yl (2c)
Pyrazoline 2c was obtained from the reaction of -1-[2-(ethyl-
oxy) phenyl]-3-(thiophen-2-yl) prop-2-en-1-one 1b 1a (0.5 g,
0.0015 mol) with phenyl hydrazine (0.730 g, 0.004 mol) under
similar conditions was used for 1a and was further crystallized
from ethanol to afford 2c.
Reddish brown; Yield: 95%; m.p.126 C; Anal. calc. for
C23H22N2O3S: C, 67.98; H, 5.41; N, 6.89; Found: C, 67.95;
H, 4.38; N, 6.85 %; IR (KBr) tmax (cm
1): 2878, 2889 (meth-
ylene C–H), 3247 (Ar-H), 3369 (N–H), 1648, 1755 (C‚N); 1H-
NMR (400 MHz, CDCl3): d (ppm): 7.8 (5H, m, Ar-H), 7.06
(2H, m, Ar-H), 7.35 (1H, d{dd}, Jpmo = 0.8, 1.9, 7.6 Hz, Ar-
H), 7.2 (3H, m, Ar-H), 6.81 (1H, s, Ar-H), 5.12 (1Hx, dd,
Jxa = 6.5 Hz, Jxb = 11.8 Hz), 3.82(1Ha, dd, Jax = 6.5 Hz,
Jab = 17.6 Hz), 3.42(1Hb, dd, Jbx = 11.8 Hz, Jba = 17.6 Hz),
4.73 (2H, s, –CH2), 4.01 (2H, q, Jvic = 7.2 Hz, –OCH2), 1.25
(3H, t, Jvic = 7.1 Hz, –CH3);
13C-NMR (400 MHz, CDCl3):
d (ppm): 190.5 (C‚O), 155.6 (C‚N), 153.4, 152.6, 150.3
144.2, 132.5, 131.9, 130.1129.8, 129.8, 128.6, 128.6, 127.3,
124.05, 125.8, 123.1, 116.7 (Ar-C), 72.2 (OCH2), 67.6 (pyr.
ring, C-5), 62.7 (pyr. ring, C-4), 63.9 (CH2), 24.5 (CH3); m/z
(M+) 407.
5.9. 1-[2-(Naphthalen-2-ylmethoxy) phenyl]-5-(thiophen-2-
yl)-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl (2d)
Pyrazoline 2d was obtained from the reaction of -1-[2-(naph-
thalen-2-ylmethoxy) phenyl]-3-(thiophen-2-yl) prop-2-en-1-
one 1b 1a (0.5 g, 0.0015 mol) with phenyl hydrazine (0.830 g,
0.0043 mol) under similar conditions was used for 1a and
was further crystallized from ethanol to afford 2d.
Reddish brown; Yield: 91%; m.p. 155 C; Anal. calc. for
C30H24N2OS: C, 78.26; H, 5.21; N, 6.08; Found: C,78.22;
H,5.18; N, 6.05%; IR (KBr) tmax (cm
1): 3257 (Ar-H), 3314
(N–H), 1586 (C‚N), 1445 (N–N); 1H-NMR (400 MHz,
CDCl3): d (ppm): 7.8 (2H, dd, Jm,o = 1.8 Hz, 7.4 Hz, Ar-H),
7.49 (5H, m, Ar-H), 7.10 (7H, m, Ar-H), 7.02 (2H, d{dd},
Jp,m,o = 0.8, 1.9, 7.6 Hz, Ar-H), 6.81 (3H, m Ar-H), 5.49
(2H, s, –CH2), 5.23 (1Hx, dd, Jxa = 6.7 Hz, Jxb = 11.6 Hz),
3.63 (1Ha, dd, Jax = 6.7 Hz, Jab = 17.2 Hz), 3.24 (1Hb, dd,
Jbx = 11.6 Hz, Jba = 17.2 Hz);
13C-NMR (400 MHz, CDCl3):
d (ppm): 156.7 (C‚N), 154.3, 153.2, 144.2, 142.2, 133.5, 131.5,
130.7, 129.2, 129.2, 128.7, 128.7, 128.1, 127.6, 127.2, 126.2,
126.2, 125.3, 124.2, 124.2, 123.9, 123.9, 123.1, 123.1, 121.2,
120.6, 118.7 (Ar-C), 71.3 (pyr. ring, C-5), 64.3 (CH2),
61.5(pyr. ring, C-4); m/z (M+) 461.
6. Conclusions
The novel pyrazoline derivatives were synthesized by the reac-
tion of alkoxy chalcones with thiosemicabazide/phenyl hydra-
zine and were studied for their antibacterial activity. This
research involves the synthesis of pyrazoline derivatives 2a–
2d of alkoxy chalcones 1a–1d and antibacterial activity of these
pyrazoline compounds were examined using culture A. hydro-
phila, Y. enterocolitica, L. monocytogenes and S. aureses. The
Synthesis, studies and in vitro antibacterial activity of some 5-(thiophene-2-yl)-phenyl pyrazoline derivatives 417results of antibacterial screening reveal that among all the
compounds screened, compounds 2a–2d and 3a–3d showed
moderate antibacterial activity while compounds 2b and 2d
displayed good antibacterial activity when compared with
Gentamicin and Tetracycline used as the standard drugs. Par-
ticularly, compound 2a which carries the allyoxy substituent
appears to exhibit the highest antibacterial activity (zone of
inhibition up to 18.4–24.3 mm) against all bacteria.
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